 In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) for the development and commercialization of products for the treatment of multiple cancer indications.In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite’s most advanced immunotherapy product candidate – KTE-C19 CAR – can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin’s lymphoma, known as diffuse large B cell lymphoma (DLBCL).The clinical data were presented at the 55th American Society of Hematology Annual Meeting.